Literature DB >> 11284917

Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin C.

M Acevedo-Duncan1, J Pearlman, B Zachariah.   

Abstract

We assessed the radiosensitivity of the grade III human glioma cell line U-373MG by investigating the effects of radiation and the specific protein kinase C inhibitor, calphostin C on the cell cycle and cell proliferation. Irradiated glioma U-373MG cells progressed through G1-S and underwent an arrest in G2-M phase. The radiosensitivity of U-373MG cells to graded doses of either photons or electrons was determine by microculture tetrazolium assay. The data was fitted to the linear-quadratic model. The proliferation curves demonstrated that U-373MG cells appear to be highly radiation resistant since 8 Gy was required to achieve 50% cell mortality. Compared to radiation alone, exposure to calphostin C (250 nM) 1 h prior to radiation decreased the proliferation of U-373MG by 76% and calphostin C provoked a weakly synergistic effect in concert with radiation. Depending on the time of application following radiation, calphostin C produced an additive or less than additive effect on cell proliferation. We postulate that the enhanced radiosensitivity observed when cells are exposed to calphostin C prior to radiation may be due to direct or indirect inhibition of protein kinase C isozymes required for cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284917      PMCID: PMC6496374          DOI: 10.1046/j.1365-2184.2001.00194.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  50 in total

1.  Inhibition of protein kinase C by calphostin C is light-dependent.

Authors:  R F Bruns; F D Miller; R L Merriman; J J Howbert; W F Heath; E Kobayashi; I Takahashi; T Tamaoki; H Nakano
Journal:  Biochem Biophys Res Commun       Date:  1991-04-15       Impact factor: 3.575

Review 2.  Cyclic x-ray responses in mammalian cells in vitro.

Authors:  W K Sinclair
Journal:  Radiat Res       Date:  1968-03       Impact factor: 2.841

3.  Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system.

Authors:  W T Couldwell; J P Antel; M L Apuzzo; V W Yong
Journal:  J Neurosurg       Date:  1990-10       Impact factor: 5.115

4.  Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway.

Authors:  G H Baltuch; V W Yong
Journal:  Brain Res       Date:  1996-02-26       Impact factor: 3.252

5.  Intact G2-phase checkpoint in cells of a human cell line lacking DNA-dependent protein kinase activity.

Authors:  J Allalunis-Turner; G M Barron; R S Day
Journal:  Radiat Res       Date:  1997-03       Impact factor: 2.841

6.  Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report.

Authors:  W Zhang; D R Hinton; A A Surnock; W T Couldwell
Journal:  Neurosurgery       Date:  1996-03       Impact factor: 4.654

7.  Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro.

Authors:  W T Couldwell; J H Uhm; J P Antel; V W Yong
Journal:  Neurosurgery       Date:  1991-12       Impact factor: 4.654

8.  Radiosensitivity testing of human malignant gliomas.

Authors:  J Ramsay; R Ward; N M Bleehen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

9.  Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation.

Authors:  D E Hallahan; S Virudachalam; M L Sherman; E Huberman; D W Kufe; R R Weichselbaum
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

10.  Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen.

Authors:  G H Baltuch; W T Couldwell; J G Villemure; V W Yong
Journal:  Neurosurgery       Date:  1993-09       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.